Skip to content
Inciteful Med

Recognizing the Signs: Symptoms and Red Flags

Last updated:

ATTRv V30M amyloidosis causes a wide range of nerve and organ symptoms. Early warning signs often include unexplained digestive issues, dizziness upon standing, and bilateral carpal tunnel syndrome. Symptoms vary significantly depending on whether the condition starts before or after age 50.

Key Takeaways

  • • Early warning signs of ATTRv V30M often involve the autonomic nervous system, causing unexplained digestive issues and dizziness.
  • • Carpal tunnel syndrome in both hands can precede an ATTRv V30M diagnosis by an average of 10 years.
  • • Early-onset disease typically presents with a loss of pain or temperature sensation, while late-onset often involves walking difficulties and heart issues.
  • • The condition is frequently misdiagnosed as CIDP, diabetic neuropathy, or wild-type amyloidosis.

When you are living with ATTRv V30M Amyloidosis, your symptoms often tell a story that began years before your diagnosis. Because this condition affects multiple systems in the body, it can produce a confusing “constellation” of signs that may not seem related at first [1][2]. Understanding these patterns can help you make sense of what you are experiencing and prepare you for conversations with your care team.

The “Invisible” Early Warning Signs

For many people, the very first symptoms are not related to muscle strength or movement, but to the autonomic nervous system—the part of your body that controls automatic functions [3].

  • Gastrointestinal (GI) Issues: Unexplained, frequent diarrhea, constipation, or alternating between the two is a major early sign [4][5]. This is often accompanied by unexplained weight loss [6].
  • Bilateral Carpal Tunnel Syndrome: Numbness or pain in both hands (carpal tunnel) is a significant “red flag.” It often precedes a formal amyloidosis diagnosis by an average of 10 years [7][8].
  • Orthostatic Hypotension: Feeling lightheaded, dizzy, or even fainting when you stand up quickly [3][9].
  • Sexual and Bladder Dysfunction: Difficulties with erectile function or changes in bladder control can be early indicators of nerve involvement [1][3].

How Symptoms Differ by Age of Onset

The V30M mutation can look different depending on when it starts. Doctors categorize these into two main groups:

Early-Onset (Typically under age 50)

In this form, the damage often starts with small-fiber axons, which carry pain and temperature signals [10].

  • Loss of Pain/Temperature Sensation: You might lose the ability to feel a “pinprick” or hot/cold temperatures before you lose the sense of touch [11].
  • Severe Autonomic Issues: GI problems and blood pressure drops are often very prominent early on [12][3].

Late-Onset (Typically over age 50)

This form often presents as a length-dependent sensorimotor neuropathy, meaning it starts at the furthest points from your spine (like your toes) and moves upward [13].

  • Walking Difficulties: You may notice muscle weakness or “foot drop” (difficulty lifting the front of your foot) earlier than in early-onset cases [13].
  • Heart Involvement: Cardiac issues, such as heart wall thickening or rhythm problems (conduction disturbances), are more common and can sometimes be the first major symptom [13][14].

The “Great Imitator”: Common Misdiagnoses

Because the symptoms of V30M are so varied, it is frequently confused with other conditions [15].

  • CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy): This is the most common misdiagnosis [15]. A key clue that it might actually be V30M is if the symptoms do not improve with standard CIDP treatments like IVIg or steroids [15][16].
  • Diabetic Neuropathy: Many patients are told their symptoms are from diabetes. However, V30M often includes heart or GI issues that are more severe than typical diabetic nerve damage [3][14].
  • SSA / Wild-Type ATTR: In older patients, V30M can look like “wild-type” amyloidosis (which is not inherited). Genetic testing is the only way to tell the difference [17][18].

What Happens Without Treatment?

Without modern disease-modifying therapy, the symptoms of V30M are progressive, meaning they worsen over time [1]. This is the historical progression before modern therapies were available:

  1. Stage 1: Symptoms are present (like numbness or GI issues), but you can still walk without assistance [19][20].
  2. Stage 2: You may need a cane or walker to move around [19][21].
  3. Stage 3: Severe disability, often requiring significant mobility assistance and help with daily activities [20].

Note: Today’s treatments are designed specifically to interrupt this historical progression, which is why identifying these “red flags” early is so vital [22][23].

Frequently Asked Questions

What are the early warning signs of ATTRv V30M amyloidosis?
Early signs often involve the autonomic nervous system, which controls automatic body functions. You may experience unexplained digestive issues like severe diarrhea or constipation, dizziness when standing up, and changes in bladder control.
Can carpal tunnel syndrome be a sign of amyloidosis?
Yes, developing carpal tunnel syndrome in both hands is a major red flag for ATTRv amyloidosis. It often occurs up to 10 years before a formal diagnosis of the disease is made.
How does early-onset V30M differ from late-onset?
Early-onset V30M usually starts before age 50 with severe digestive issues and a loss of pain or temperature sensation. Late-onset typically begins after age 50 and often presents with walking difficulties, foot drop, and heart problems.
Why is ATTRv V30M often misdiagnosed as CIDP?
ATTRv V30M causes nerve damage that can look very similar to CIDP. However, a major clue that the condition is actually ATTRv V30M is when nerve symptoms do not improve with standard CIDP immune treatments like IVIg or steroids.

Questions for Your Doctor

  • • Does my pattern of symptoms (e.g., small-fiber vs. large-fiber) suggest an early-onset or late-onset form of V30M?
  • • Since I have bilateral carpal tunnel syndrome, how long ago do you suspect the amyloid process might have started?
  • • Are the gastrointestinal issues I'm experiencing related to autonomic nerve damage from the amyloid?
  • • If I was previously diagnosed with CIDP, why did I not respond to the standard treatments like IVIg?
  • • What specific 'red flag' symptoms should I be monitoring for that indicate my heart might be becoming involved?

Questions for You

  • • Have you noticed 'invisible' symptoms like feeling dizzy when you stand up, changes in how much you sweat, or frequent diarrhea and constipation?
  • • Did you have surgery for carpal tunnel syndrome on both hands years before your other symptoms started?
  • • Have you experienced unexplained weight loss or a significant drop in your energy levels recently?
  • • When you feel pain or numbness, did it start in your toes and slowly move up your legs, or did it affect your hands and feet at the same time?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Late-onset Transthyretin (TTR)-familial Amyloid Polyneuropathy (FAP) with a Long Disease Duration from Non-endemic Areas in Japan.

    Miyake Z, Nakamagoe K, Ezawa N, et al.

    Internal medicine (Tokyo, Japan) 2019; (58(5)):713-718 doi:10.2169/internalmedicine.1457-18.

    PMID: 30333406
  2. 2

    Diagnosis and Treatment of Hereditary Transthyretin Amyloidosis (hATTR) Polyneuropathy: Current Perspectives on Improving Patient Care.

    Luigetti M, Romano A, Di Paolantonio A, et al.

    Therapeutics and clinical risk management 2020; (16()):109-123 doi:10.2147/TCRM.S219979.

    PMID: 32110029
  3. 3

    Autonomic involvement in hereditary transthyretin amyloidosis (hATTR amyloidosis).

    Gonzalez-Duarte A

    Clinical autonomic research : official journal of the Clinical Autonomic Research Society 2019; (29(2)):245-251 doi:10.1007/s10286-018-0514-2.

    PMID: 29511897
  4. 4

    Gastrointestinal Manifestations in Hereditary Transthyretin Amyloidosis associated with Glu89Gln Mutation.

    Nakov R, Sarafov S, Nakov V, et al.

    Journal of gastrointestinal and liver diseases : JGLD 2019; (28(4)):421-426 doi:10.15403/jgld-362.

    PMID: 31826067
  5. 5

    Patient-reported burden of hereditary transthyretin amyloidosis on functioning and well-being.

    Lovley A, Raymond K, Guthrie SD, et al.

    Journal of patient-reported outcomes 2021; (5(1)):3 doi:10.1186/s41687-020-00273-y.

    PMID: 33411323
  6. 6

    Red flags in patients with hereditary transthyretin amyloidosis at diagnosis in a non-endemic area of Spain.

    Silva-Hernández L, Horga Hernández A, Valls Carbó A, et al.

    Neurologia 2023; (38(2)):87-92 doi:10.1016/j.nrleng.2020.06.015.

    PMID: 36396096
  7. 7

    Carpal tunnel syndrome and associated symptoms as first manifestation of hATTR amyloidosis.

    Karam C, Dimitrova D, Christ M, Heitner SB

    Neurology. Clinical practice 2019; (9(4)):309-313 doi:10.1212/CPJ.0000000000000640.

    PMID: 31583185
  8. 8

    Exertional chest pain is sometimes more than just coronary atherosclerosis.

    Morgado GJ, Gomes AC, Cruz IR, et al.

    Revista portuguesa de cardiologia 2021; (40(3)):245.e1-245.e5 doi:10.1016/j.repc.2021.02.002.

    PMID: 33715921
  9. 9

    Cardiac and peripheral vasomotor autonomic functions in late-onset transthyretin Val30Met familial amyloid polyneuropathy.

    Koike H, Nakamura T, Hashizume A, et al.

    Journal of neurology 2017; (264(11)):2293-2302 doi:10.1007/s00415-017-8629-2.

    PMID: 28983659
  10. 10

    Schwann cell and endothelial cell damage in transthyretin familial amyloid polyneuropathy.

    Koike H, Ikeda S, Takahashi M, et al.

    Neurology 2016; (87(21)):2220-2229 doi:10.1212/WNL.0000000000003362.

    PMID: 27794111
  11. 11

    Kind and distribution of cutaneous sensation loss in hereditary transthyretin amyloidosis with polyneuropathy.

    Pinto MV, Dyck PJB, Gove LE, et al.

    Journal of the neurological sciences 2018; (394()):78-83 doi:10.1016/j.jns.2018.08.031.

    PMID: 30219500
  12. 12

    Baseline disease characteristics in Brazilian patients enrolled in Transthyretin Amyloidosis Outcome Survey (THAOS).

    Cruz MW, Pinto MV, Pinto LF, et al.

    Arquivos de neuro-psiquiatria 2019; (77(2)):96-100 doi:10.1590/0004-282X20180156.

    PMID: 30810593
  13. 13

    Characteristics of Patients with Late- vs. Early-Onset Val30Met Transthyretin Amyloidosis from the Transthyretin Amyloidosis Outcomes Survey (THAOS).

    Waddington-Cruz M, Wixner J, Amass L, et al.

    Neurology and therapy 2021; (10(2)):753-766 doi:10.1007/s40120-021-00258-z.

    PMID: 34024024
  14. 14

    Phenotypes of Late-Onset Transthyretin Amyloid Neuropathy: A Diagnostic Challenge.

    Živković SA, Mnatsakanova D, Lacomis D

    Journal of clinical neuromuscular disease 2019; (21(1)):1-6 doi:10.1097/CND.0000000000000252.

    PMID: 31453848
  15. 15

    Prevalence of hereditary transthyretin amyloidosis in CIDP patients with red flags: a multicenter genetic screening and misdiagnosis analysis.

    Doneddu PE, Moretti G, Di Stefano V, et al.

    Journal of neurology 2025; (272(8)):515 doi:10.1007/s00415-025-13218-6.

    PMID: 40670759
  16. 16

    Diagnosis of hereditary transthyretin amyloidosis in patients with suspected chronic inflammatory demyelinating polyneuropathy unresponsive to intravenous immunoglobulins: results of a retrospective study.

    Péréon Y, Adams D, Camdessanché JP, et al.

    Orphanet journal of rare diseases 2025; (20(1)):95 doi:10.1186/s13023-025-03589-4.

    PMID: 40025610
  17. 17

    Late-Onset Hereditary Transthyretin Amyloidosis Val30Met in an Elderly Person in a Non-Endemic Area.

    Wang S, Sun J, Lu Q, et al.

    International medical case reports journal 2022; (15()):299-306 doi:10.2147/IMCRJ.S357236.

    PMID: 35734096
  18. 18

    Single-centre experience on transthyretin familial amyloid polyneuropathy: case series and literature review.

    Martens B, De Pauw M, De Bleecker JL

    Acta neurologica Belgica 2018; (118(2)):179-185 doi:10.1007/s13760-018-0906-z.

    PMID: 29524093
  19. 19

    Tegsedi (Inotersen): An Antisense Oligonucleotide Approved for the Treatment of Adult Patients with Hereditary Transthyretin Amyloidosis.

    Gales L

    Pharmaceuticals (Basel, Switzerland) 2019; (12(2)) doi:10.3390/ph12020078.

    PMID: 31117178
  20. 20

    Hereditary transthyretin-mediated amyloidosis with polyneuropathy: baseline anthropometric, demographic and disease characteristics of patients from a reference center.

    Sequeira VCC, Penetra MA, Duarte L, et al.

    Arquivos de neuro-psiquiatria 2022; (80(3)):262-269 doi:10.1590/0004-282X-ANP-2020-0590.

    PMID: 34755769
  21. 21

    Vutrisiran: First Approval.

    Keam SJ

    Drugs 2022; (82(13)):1419-1425 doi:10.1007/s40265-022-01765-5.

    PMID: 35997942
  22. 22

    New insights into the clinical evaluation of hereditary transthyretin amyloidosis patients: a single center's experience.

    Suhr OB, Gustavsson S, Heldestad V, et al.

    Degenerative neurological and neuromuscular disease 2012; (2()):93-106 doi:10.2147/DNND.S24652.

    PMID: 30890882
  23. 23

    Population Pharmacokinetic-Pharmacodynamic Modeling of Inotersen, an Antisense Oligonucleotide for Treatment of Patients with Hereditary Transthyretin Amyloidosis.

    Yu RZ, Collins JW, Hall S, et al.

    Nucleic acid therapeutics 2020; (30(3)):153-163 doi:10.1089/nat.2019.0822.

    PMID: 32286934

This page explains the symptoms and progression of ATTRv V30M amyloidosis for educational purposes. Always consult your healthcare provider or a specialist for an accurate diagnosis and treatment plan.

Stay up to date

Get notified when new research about ATTRV30M amyloidosis is published.

No spam. Unsubscribe anytime.